Vifor Pharma AG (VIFN.SW)
Chart Events
Performance Outlook
| Previous Close | 168.55 |
| Open | 169.45 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's Range | 168.55 - 169.45 |
| 52 Week Range | 102.30 - 197.20 |
| Volume | |
| Avg. Volume | 42,161 |
| Market Cap | 11.025B |
| Beta (5Y Monthly) | 1.37 |
| PE Ratio (TTM) | 26.38 |
| EPS (TTM) | 6.40 |
| Earnings Date | Mar 01, 2022 - Mar 07, 2022 |
| Forward Dividend & Yield | 2.00 (1.17%) |
| Ex-Dividend Date | Apr 29, 2022 |
| 1y Target Est | 160.76 |
- Business Wire
Finalization of Vifor Pharma acquisition
MELBOURNE, Australia & ST. GALLEN, Switzerland, August 02, 2022--Regulatory News: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220801005796/en/
- Business Wire
Extension of the postponement of the settlement of Vifor Pharma tender offer
MELBOURNE, Australia & ST. GALLEN, Switzerland, July 13, 2022--Regulatory News: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220712006199/en/
- Reuters
UPDATE 1-EU regulators investigate Vifor Pharma over anti-competitive behaviour
EU antitrust regulators are investigating whether Vifor Pharma, which is being acquired by CSL Ltd, disparaged its rival Pharmacosmos in order to hinder competition to its blockbuster iron medicine Ferinject. The European Commission, which opened the probe on Monday, said it has indications of this behaviour going on for many years, which may be in breach of EU rules against companies abusing their dominant position. The EU competition enforcer said it was concerned that Vifor Pharma pursued a misleading communication campaign, primarily targeting healthcare professionals.
